CMap Candidate Details

Structure:
CMap ID: C01255
Pert ID: BRD-A52530684
Compound Name: doxorubicin
Targets: TOP2A
MoA: Topoisomerase inhibitor
SMILES: COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](OC5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO
InchiKey: AOJJSUZBOXZQNB-BLSUDJMZSA-N
Compound Aliases: --

Score ID Pert ID Cell Line Pert Dose Pert Time Raw Score (GSE126848) Normalized Score (GSE126848) fdr_q_nlog10 (GSE126848) Raw Score (GSE135251) Normalized Score (GSE135251) fdr_q_nlog10 (GSE135251)
44648 BRD-A52530684 A549 10 uM 6 h -0.32 -1.34 0.96 0.21 0.75 0.04
44773 BRD-A52530684 ASC 10 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
45366 BRD-A52530684 HT29 10 uM 6 h 0.0 0.0 0.0 0.3 1.07 0.63
46208 BRD-A52530684 PHH 10 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
46523 BRD-A52530684 SKB 10 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
87321 BRD-A52530684 BJAB 10 uM 6 h 0.0 0.0 0.0 0.0 0.0 0.0
87346 BRD-A52530684 HBL1 0.125 uM 24 h 0.24 1.0 0.11 0.0 0.0 0.0
87396 BRD-A52530684 K562 0.04 uM 24 h 0.0 0.0 0.0 0.33 1.18 0.97
87443 BRD-A52530684 KMS34 0.04 uM 24 h 0.0 0.0 0.0 0.35 1.25 1.29
87483 BRD-A52530684 MINO 0.04 uM 24 h 0.0 0.0 0.0 0.25 0.87 0.17
87547 BRD-A52530684 NALM6 0.01 uM 24 h 0.0 0.0 0.0 -0.27 -0.92 0.34
87598 BRD-A52530684 OCILY10 0.04 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
87648 BRD-A52530684 OCILY19 0.04 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
87700 BRD-A52530684 OCILY3 0.125 uM 24 h -0.21 -0.86 0.02 0.0 0.0 0.0
87747 BRD-A52530684 SKMEL5 0.66 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
87785 BRD-A52530684 THP1 0.04 uM 24 h -0.26 -1.08 0.29 -0.27 -0.89 0.27
87865 BRD-A52530684 TMD8 10 uM 6 h -0.29 -1.2 0.56 0.0 0.0 0.0
119384 BRD-A52530684 A375 10 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
119449 BRD-A52530684 HA1E 3.33 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
119481 BRD-A52530684 HCC515 0.12 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
119517 BRD-A52530684 HEPG2 3.33 uM 24 h 0.0 0.0 0.0 0.27 0.97 0.35
119585 BRD-A52530684 MCF??7.00 10 uM 24 h 0.0 0.0 0.0 0.0 0.0 0.0
119615 BRD-A52530684 PC3 0.04 uM 24 h 0.23 0.97 0.08 0.0 0.0 0.0
The GSE89632 and GSE126848 datasets are hepatic gene expression profiles of nonalcoholic fatty liver disease (NAFLD).